Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy

This publication has 34 references indexed in Scilit:

• Immunisation with recombinant modified vaccinia virus Ankara expressing HIV‐1 gag in HIV‐1‐infected subjects stimulates broad functional CD4⁺ T cell responses
  European Journal of Immunology, 2006
• Expansion and Diversification of Virus-Specific T Cells following Immunization of Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Individuals with a Recombinant Modified Vaccinia Virus Ankara/HIV-1 Gag Vaccine
  Journal of Virology, 2006
• Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers
  Vaccine, 2006
• Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094)
  Vaccine, 2005
• A Randomised, Double-Blind, Controlled Vaccine Efficacy Trial of DNA/MVA ME-TRAP Against Malaria Infection in Gambian Adults
  PLoS Medicine, 2004
• Phase 1 Evaluation of 3 Highly Immunogenic Prime‐Boost Regimens, Including a 12‐Month Reboosting Vaccination, for Malaria Vaccination in Gambian Men
  The Journal of Infectious Diseases, 2004
• Unintended Smallpox Vaccination of HIV-1--Infected Individuals in the United States Military
  Clinical Infectious Diseases, 2004
• Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study
  HIV Medicine, 2003
• Immune Activation and Virologic Response to Immunization in Recent HIV Type 1 Seroconverters
  AIDS Research and Human Retroviruses, 1999
• Disseminated Vaccinia in a Military Recruit with Human Immunodeficiency Virus (HIV) Disease
  New England Journal of Medicine, 1987